Showing results (11-20 of 150) with videos related to
Sort By:
Pageof 15
Metabolomics : Official Journal of the Metabolomic Society|April 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulationAkos Pal, Yasmin Asad, Ruth Ruddle, et al.Cancer Research|January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitorsVictoria E Anderson, Michael I Walton, Paul D Eve, et al.Expert Opinion on Therapeutic Patents|May 24, 2011
Checkpoint kinase inhibitors: a patent review (2009 - 2010)Michael Lainchbury, Ian CollinsChemistry & Biology|July 9, 2010
Probing the probes: fitness factors for small molecule toolsPaul Workman, Ian CollinsFuture Medicinal Chemistry|August 4, 2012
Macrocycles in new drug discoveryJamie Mallinson, Ian CollinsNature Chemical Biology|November 17, 2006
New approaches to molecular cancer therapeuticsIan Collins, Paul WorkmanFuture Medicinal Chemistry|February 17, 2015
Photoaffinity labeling in target- and binding-site identificationEwan Smith, Ian CollinsFuture Medicinal Chemistry|July 9, 2019
Labelled chemical probes for demonstrating direct target engagement in living systemsHugues Prevet, Ian CollinsJournal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.International Journal of Radiation Oncology, Biology, Physics|September 18, 2012
Targeted radiosensitization by the Chk1 inhibitor SAR-020106Gerben R Borst, Martin McLaughlin, Joan N Kyula, et al.Pageof 15